{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:03:24Z","timestamp":1784171004213,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Patients with <jats:italic toggle=\"yes\">BRAF<\/jats:italic> V600 (<jats:italic toggle=\"yes\">BRAF<\/jats:italic>) mutated metastatic melanoma are eligible for therapy with both immune checkpoint inhibitors and targeted therapies, making treatment choice a complex decision. The present study aimed to describe patterns of treatment with immunotherapy and targeted therapy and <jats:italic toggle=\"yes\">BRAF<\/jats:italic> testing in patients with metastatic melanoma presumed to have <jats:italic toggle=\"yes\">BRAF<\/jats:italic> mutations (<jats:italic toggle=\"yes\">BRAF<\/jats:italic>+) in the years following the approval of the newer generation of immune checkpoint inhibitors and targeted therapies (2014\u20132016). Two large US commercial claims databases [Truven Health Analytics MarketScan and IQVIA Real-World Data Adjudicated Claims \u2013 USA (IQVIA RWD Adjudicated Claims \u2013 USA)] were used. Patients were presumed <jats:italic toggle=\"yes\">BRAF<\/jats:italic>+ if they received at least 2 lines of therapy of which at least 1 included targeted therapy. Sequence of lines of therapy and regimens used in first (1L), second (2L), and third (3L), as well as timing of <jats:italic toggle=\"yes\">BRAF<\/jats:italic> testing by sequence of therapy were described. In the Truven sample (<jats:italic toggle=\"yes\">n<\/jats:italic>=162), targeted therapy was used by 66% in 1L and by 54% in 2L, and 62% had a <jats:italic toggle=\"yes\">BRAF<\/jats:italic> test; in the IQVIA RWD Adjudicated Claims \u2013 USA sample (<jats:italic toggle=\"yes\">n<\/jats:italic>=247), targeted therapy was used by 62% in 1L and by 50% in 2L, and 68% had a <jats:italic toggle=\"yes\">BRAF<\/jats:italic> test. Among those with a claim for a <jats:italic toggle=\"yes\">BRAF<\/jats:italic> test prior to 1L, over two-thirds were initiated on targeted therapy. These findings suggest that the rate of <jats:italic toggle=\"yes\">BRAF<\/jats:italic> testing remained low in the years following the approval of <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-targeted regimens for metastatic disease. Given the recently approved adjuvant treatment options for stage III melanoma, improving the rates of <jats:italic toggle=\"yes\">BRAF<\/jats:italic> testing becomes increasingly important.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000504","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T20:42:46Z","timestamp":1537994566000},"page":"301-310","source":"Crossref","is-referenced-by-count":6,"title":["Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive"],"prefix":"10.1097","volume":"29","author":[{"given":"Sameer","family":"Ghate","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Burne","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Ndife","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nakasato","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjd.12504","article-title":"The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort","volume":"169","author":"Ekedahl","year":"2013","journal-title":"Br J Dermatol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamaoncol.2016.4877","article-title":"Systemic therapy for previously untreated advanced BRAF-mutated melanoma: a systematic review and network meta-analysis of randomized clinical trials","volume":"3","author":"Devji","year":"2017","journal-title":"JAMA Oncol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jdv.12910","article-title":"Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma","volume":"29","author":"Pracht","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00262-012-1227-3","article-title":"Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab","volume":"61","author":"Shahabi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/imt-2017-0023","article-title":"Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape","volume":"9","author":"Levine","year":"2017","journal-title":"Immunotherapy"},{"key":"R24-20230902","first-page":"1223","article-title":"Systemic therapy of metastatic melanoma","volume":"13","author":"Rauschenberg","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"R25-20230902","article-title":"White paper: Health research data for the real","author":"Hansen"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1634\/theoncologist.2014-0059","article-title":"Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting","volume":"19","author":"Hurvitz","year":"2014","journal-title":"Oncologist"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/lmt.15.12","article-title":"First-, second- and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database","volume":"1","author":"Ramsey","year":"2015","journal-title":"Lung Cancer Manag Future Med"},{"key":"R28-20230902","first-page":"461","article-title":"Medical costs associated with use of systemic therapy in adults with colorectal cancer","volume":"19","author":"Seal","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/cam4.475","article-title":"Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting","volume":"4","author":"Gibney","year":"2015","journal-title":"Cancer Med"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"R32-20230902","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cup.12364","article-title":"Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma","volume":"41","author":"Pearlstein","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3390\/jpm8020019","article-title":"Insurance coverage policies for pharmacogenomic and multi-gene testing for cancer","volume":"8","author":"Lu","year":"2018","journal-title":"J Pers Med"},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/jama.2018.4863","article-title":"Evolving payer coverage policies on genomic sequencing tests: beginning of the end or end of the beginning?","volume":"319","author":"Phillips","year":"2018","journal-title":"JAMA"},{"key":"R41-20230902","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/cup.13126","article-title":"Molecular testing practices and perceptions among dermatopathologists","volume":"45","author":"Torre","year":"2018","journal-title":"J Cutan Pathol"},{"key":"R42-20230902","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.3390\/jpm7040017","article-title":"Access to guideline-recommended pharmacogenomic tests for cancer treatments: experience of providers and patients","volume":"7","author":"Wu","year":"2017","journal-title":"J Pers Med"},{"key":"R43-20230902","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201906000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:28:55Z","timestamp":1693625335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201906000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000504","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}